52,850 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 52,850 shares of the life sciences company’s stock, valued at approximately $960,000. GSA Capital Partners LLP owned approximately 0.07% of Integra LifeSciences as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Versor Investments LP purchased a new stake in Integra LifeSciences in the third quarter worth $612,000. Olstein Capital Management L.P. boosted its holdings in shares of Integra LifeSciences by 37.2% during the 3rd quarter. Olstein Capital Management L.P. now owns 155,000 shares of the life sciences company’s stock valued at $2,816,000 after buying an additional 42,000 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Integra LifeSciences by 18.7% in the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock worth $7,294,000 after buying an additional 63,266 shares during the period. New York State Teachers Retirement System increased its stake in shares of Integra LifeSciences by 3.0% in the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock worth $1,637,000 after acquiring an additional 2,616 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in Integra LifeSciences by 144.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company’s stock valued at $2,393,000 after acquiring an additional 77,825 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup boosted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. JMP Securities reduced their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Finally, Bank of America dropped their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and a consensus price target of $24.00.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $22.88 on Friday. The firm has a market capitalization of $1.77 billion, a PE ratio of -254.22, a P/E/G ratio of 0.79 and a beta of 1.08. The company has a 50 day moving average price of $19.54 and a 200-day moving average price of $24.21. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $45.42. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same period in the previous year, the business earned $0.76 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. As a group, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.